MacroGenics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MGNX | PYXS | ADAG | HBP.TO | HURA | SCLP.L | |
|---|---|---|---|---|---|---|
| Market cap | 147.15M | 198.30M | 161.82M | 70.27M | 109.61M | 116.66M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.6 | -1.5 | -4.3 | -8.4 | -2.8 | -370.6 |
| Price/book | 3.4 | 9.2 | 1.8 | 4.8 | 6.0 | -4.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +69.85% | −58.91% | +49.69% | −54.68% | −29.80% | −13.71% |
| Today | −0.86% | +1.22% | +2.55% | 0.00% | +3.93% | +1.16% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MGNX news ›FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage…
Rockville’s MacroGenics Reports Encouraging Phase 2 Cancer Results as LINNET Trial Advances After Safety Hold
Rockville's MacroGenics Reports Encouraging Phase 2 Cancer Results as LINNET Trial Advances After Safety Hold BioBuzz Rockville’s MacroGenics Reports Encouraging Phase 2 Cancer Results as LINNET Trial Advances After Safety Hold Rockville,…
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
Among 16 response-evaluable patients with CCGC, the confirmed objective response rate (ORR) was 25% (4/16), and the disease control rate was 44% (7/16). All responses remained ongoing at data cutoff. In the 17 safety-evaluable patients…
Head to Head Review: MacroGenics (MGNX) and Its Peers
Posted by Danessa Lincoln on Oct 28th, 2026 MacroGenics (NASDAQ:MGNX – Get Free Report) is one of 847 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare MacroGenics to similar…
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
Overall MGC026 Safety and Dose Selection As part of the Phase 1 study, MacroGenics is evaluating MGC026 in an ongoing Simon's 2-stage tumor-specific expansion cohort in recurrent/metastatic SCCHN. The study is designed to enroll 40…
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
ROCKVILLE, MD, Oct. 15, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on develop... MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with…
MacroGenics announces interim data from MGC026 study
MacroGenics (MGNX) announced interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate, or ADC, in patient... MacroGenics announces interim data from MGC026 study MacroGenics (MGNX) announced interim…
MacroGenics, Inc. (NASDAQ:MGNX) Stock Now Rated “Hold” by Sell-Side Analysts
Posted by Tristan Rich on Oct 24th, 2026 Check Out Our Latest Stock Analysis on MacroGenics Shares of MGNX opened at $2.25 on Friday. MacroGenics has a 52 week low of $1.29 and a 52 week high of $5.08. The stock has a market capitalization…
First patient dosed in MacroGenics’ Phase I MGC030 trial
The trial will enrol up to 54 patients in the initial escalation phase. US-based clinical-stage biopharmaceutical company MacroGenics has dosed the first patient in a Phase I study of its investigational therapy, MGC030, for advanced solid…
MacroGenics' Bonvini exercises options for 8,000 shares
Ericsson reports third quarter results 2026 AIR Announces Capital Return Framework The option schedule makes 12.5% of the grant exercisable after six months, followed by an additional 6.25% each three-month period. MacroGenics' Sr VP,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com6
- themarketsdaily.com3
- defenseworld.net1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.